Open AccessAssociation of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults
Author(s) -
Alexandra J. Weigand,
Mark W. Bondi,
Kelsey R. Thomas,
Noll L. Campbell,
Douglas Galasko,
David P. Salmon,
Daniel D. Sewell,
James B. Brewer,
Howard Feldman,
Lisa DelanoWood
Publication year - 2020
Publication title -
neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.91
H-Index - 364
eISSN - 1526-632X
pISSN - 0028-3878
DOI - 10.1212/wnl.0000000000010643
Subject(s) - anticholinergic , medicine , cognition , proportional hazards model , apolipoprotein e , cognitive decline , hazard ratio , incidence (geometry) , psychology , risk factor , disease , cardiology , dementia , oncology , psychiatry , confidence interval , physics , optics
To determine the cognitive consequences of anticholinergic medications (aCH) in cognitively normal older adults as well as interactive effects of genetic and CSF Alzheimer disease (AD) risk factors.